Risk stratification in chronic thromboembolic pulmonary hypertension predicts survival

Author:

Sandqvist Anna12,Kylhammar David3,Bartfay Sven-Erik45,Hesselstrand Roger6,Hjalmarsson Clara45,Kavianipour Mohammad7,Nisell Magnus89,Rådegran Göran1011,Wikström Gerhard12,Kjellström Barbro131415,Söderberg Stefan16

Affiliation:

1. Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden

2. Actelion a Division of Janssen-Cilag AB, Stockholm, Sweden

3. Department of Medical and Health Sciences and department of Clinical Physiology, Linköping University, Linköping, Sweden

4. Department of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

5. Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

6. Department of Clinical Sciences Section of Rheumatology, Lund University, Lund, Sweden

7. Department of Public Health and Clinical Medicine, Sundsvall Research Unit, Umeå University, Umeå, Sweden

8. Department of Medicine Solna, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden

9. The Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden

10. Department of Clinical Sciences Lund, Cardiology, Lund University, Lund, Sweden

11. The Section for Heart Failure and Valvular Disease, VO Heart and Lung Medicine, Skåne University Hospital, Lund, Sweden

12. Department of Medical Sciences, Cardiology, Uppsala University, Uppsala University Hospital, Uppsala, Sweden

13. Department of Medicine, Cardiology Unit, Karolinska Institute, Stockholm, Sweden

14. Department of Clinical Sciences Lund, Clinical Physiology, Lund University, Lund, Sweden

15. Skåne University Hospital, Lund, Sweden

16. Department of Public Health and Clinical Medicine, and Heart Centre, Umeå University, Umeå, Sweden

Funder

Swedish Society for Pulmonary Hypertension

Actelion Pharmaceuticals Sweden AB

Bayer Health Care

Eli Lilly Sweden

GlaxoSmithKline AB

Nordic Infu Care

Pfizer AB

Swedish Society

Actelion

United Therapeutics

Astra Zeneca

Boehringer Ingelheim

NordicInfu Care

Novartis

Pfizer

Takeda

Sandoz/Novartis

Eli-Lilly

Sanofi-Aventis

Orion Pharma

Glaxo-SmithKline AB

Publisher

Informa UK Limited

Subject

Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3